These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 31904119)

  • 1. Dravet syndrome: Treatment options and management of prolonged seizures.
    Cross JH; Caraballo RH; Nabbout R; Vigevano F; Guerrini R; Lagae L
    Epilepsia; 2019 Dec; 60 Suppl 3():S39-S48. PubMed ID: 31904119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stiripentol in Dravet syndrome: results of a retrospective U.S. study.
    Wirrell EC; Laux L; Franz DN; Sullivan J; Saneto RP; Morse RP; Devinsky O; Chugani H; Hernandez A; Hamiwka L; Mikati MA; Valencia I; Le Guern ME; Chancharme L; de Menezes MS
    Epilepsia; 2013 Sep; 54(9):1595-604. PubMed ID: 23848835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stiripentol for the treatment of seizures associated with Dravet syndrome.
    Chiron C
    Expert Rev Neurother; 2019 Apr; 19(4):301-310. PubMed ID: 30900478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current therapeutic procedures in Dravet syndrome.
    Chiron C
    Dev Med Child Neurol; 2011 Apr; 53 Suppl 2():16-8. PubMed ID: 21504427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Dravet Syndrome.
    Wirrell EC
    Can J Neurol Sci; 2016 Jun; 43 Suppl 3():S13-8. PubMed ID: 27264138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stiripentol for the treatment of seizures in Dravet syndrome.
    Eschbach K; Knupp KG
    Expert Rev Clin Pharmacol; 2019 May; 12(5):379-388. PubMed ID: 31017478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
    Guerrini R; Chiron C; Vandame D; Linley W; Toward T
    Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen.
    Dressler A; Trimmel-Schwahofer P; Reithofer E; Mühlebner A; Gröppel G; Reiter-Fink E; Benninger F; Grassl R; Feucht M
    Epilepsy Res; 2015 Jan; 109():81-9. PubMed ID: 25524846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan.
    Inoue Y; Ohtsuka Y;
    Epilepsy Res; 2015 Jul; 113():90-7. PubMed ID: 25986195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome.
    Aras LM; Isla J; Mingorance-Le Meur A
    Epilepsy Behav; 2015 Mar; 44():104-9. PubMed ID: 25666511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications.
    Lopez JC; Pare JR; Blackmer AB; Orth LE
    J Pediatr Health Care; 2022; 36(5):479-488. PubMed ID: 35987555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome.
    Buck ML; Goodkin HP
    Ann Pharmacother; 2019 Nov; 53(11):1136-1144. PubMed ID: 31167540
    [No Abstract]   [Full Text] [Related]  

  • 13. Changing Landscape of Dravet Syndrome Management: An Overview.
    Samanta D
    Neuropediatrics; 2020 Apr; 51(2):135-145. PubMed ID: 32079034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome.
    Morimoto M; Shimakawa S; Hashimoto T; Kitaoka T; Kyotani S
    J Clin Pharm Ther; 2018 Aug; 43(4):571-573. PubMed ID: 29265387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence.
    Inoue Y; Ohtsuka Y;
    Epilepsy Res; 2014 May; 108(4):725-31. PubMed ID: 24630050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stiripentol (Diacomit) for Dravet syndrome.
    Med Lett Drugs Ther; 2021 Mar; 63(1620):e48-e50. PubMed ID: 33976090
    [No Abstract]   [Full Text] [Related]  

  • 17. Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis.
    Elliott J; McCoy B; Clifford T; Wells GA; Coyle D
    Pharmacoeconomics; 2018 Oct; 36(10):1253-1261. PubMed ID: 29761351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy for Dravet Syndrome.
    Wallace A; Wirrell E; Kenney-Jung DL
    Paediatr Drugs; 2016 Jun; 18(3):197-208. PubMed ID: 26966048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stiripentol: A Review in Dravet Syndrome.
    Frampton JE
    Drugs; 2019 Nov; 79(16):1785-1796. PubMed ID: 31617141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP2C19 Phenotypes on Clinical Efficacy of Stiripentol in Japanese Patients With Dravet Syndrome.
    Yamamoto Y; Takahashi Y; Ikeda H; Imai K; Kagawa Y; Inoue Y
    Ther Drug Monit; 2020 Apr; 42(2):302-308. PubMed ID: 31318844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.